Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OncoNanoBBB

Financiado

Cerrado

Development and evaluation of a quantitative imaging technique for assessment of...

Development and evaluation of a quantitative imaging technique for assessment of nanoparticle drug delivery across the blood brain barrier Applications for brain cancer therapeutics The partners wish to build a long term European, Industry-Academia consortium, to work on the problem of delivering therapeutic agents, e.g. for brain cancer, across the blood-brain barrier (BBB) at the efficacious dose. Current t... ver más

31/12/2015

TEI-A

850K€

Presupuesto del proyecto: 850K€

Líder del proyecto

TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-12-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

TEI-A

0.00€ | Lider

UNIVERSITY OF BRIGHTON

N.D. | Participante

PPS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MOCHA Commercial feasibility of triggered liposomal drug delivery... 157K€ Cerrado

PID2019-105531RB-I00 NANOTRANSPORTADORES LIPIDICOS FUNCIONALIZADOS CON CANNABIDIO... 109K€ Cerrado

CPP2021-008871 Phase I clinical trial of a new antitumor therapy based on n... 2K€ Cerrado

PTQ-10-04214 Utilización de moléculas de carácter lipídico con fines anti... 80K€ Cerrado

Golden-ADC An Insulin-Gold Nanoplatform as Enhanced Antibody-Drug Conju... Cerrado

RTI2018-097345-B-I00 EN BUSCA DE UNA NUEVA GENERACION DE AGENTES ANTICANCEROSOS M... 71K€ Cerrado

Líder del proyecto

TECHNOLOGIKO EKPAIDEFTIKO IDRYMA ATHINAS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 850K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The partners wish to build a long term European, Industry-Academia consortium, to work on the problem of delivering therapeutic agents, e.g. for brain cancer, across the blood-brain barrier (BBB) at the efficacious dose. Current treatment options for brain cancer are limited with patients having a poor prognosis. One of the major hurdles is the BBB which prevents effective doses of drugs reaching the site of disease. There is thus a major need for technologies that can successfully overcome such a hurdle without having a negative effect on safety and tolerability. Pharmidex have developed a drug delivery system that transiently and reversibly opens the BBB to entry of compounds into the brain without inducing tissue injury. It is based on patented lipid-like structures and has been shown to deliver both small molecules and large proteins effectively into the brain. The lead delivery compound for brain cancer appears to be safe and well tolerated on the basis of pre-clinical testing. We initially seek to determine the mechanism of action of the technology for penetrating the BBB; application to different therapeutic agents as well as development of reliable brain cancer animal models to quantify efficacy of nanoparticle-based therapy using imaging technology. We believe this novel delivery technology will be a unique drug discovery tool with the potential to enhance efficacy of established agents, reduce systemic exposure of the chemotherapeutic agent, thus minimising both the on/off-target toxicity through enhancement of drug absorption at the target site. Besides its scientific objectives, OncoNanoBBB will provide a framework for cooperation and knowledge sharing between a pharmaceutical industry and two academic institutions with complementary expertise in project objectives, as well as dissemination of project outcomes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores